A Randomised, Double Blind, Placebo-controlled, Multiple Dose, Phase 2b, 24 Week Trial Followed by an Open Label Extension of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate
Phase of Trial: Phase II
Latest Information Update: 22 Sep 2015
At a glance
- Drugs Fletikumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 10 Jun 2017 Biomarkers information updated
- 04 Dec 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 29 Nov 2013 Planned end date changed from 1 Dec 2015 to 1 Feb 2015 as reported by ClinicalTrials.gov.